We are monitoring the impact of COVID-19 on Europe Gene Therapy Market Get in touch with us for detailed analysis Know More
Pulished Date May, 2021
ID: 11531
Share on
Share on

Europe Gene Therapy Market Research Report - Segmented By Vector Type, Application and Country (United Kingdom, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands and Rest of Europe) - Industry Size, Share, Trends, COVID-19 Impact & Forecast (2021 to 2026)

Pulished: May, 2021
ID: 11531
Pages: 90

Europe Gene Therapy Market Size (2021 to 2026)

The European Gene Therapy Market size is estimated to be growing at a CAGR of 24.6% between 2021 to 2026.

The European gene therapy market is expected to be driven by the factors such as the growing incidence of cancer, other target diseases, and growing new pipeline developments for gene therapy. Gene therapies have brought a revolutionary change in the field of health science and pharmaceuticals. Rising government support and financing activities for improved healthcare facilities in developed countries such as Germany, the United Kingdom, France, and Italy and increased research and development activities by researchers and industry players are projected to further propel the gene therapy market. The active participation of major industry players has resulted in adopting strategies such as productivity growth and product launch to strengthen their presence in the European regional market. Accelerating clinical trials, introducing new drugs to the market, partnerships, and product creation positively impact market growth in European countries.

Gene therapy includes repairing, repressing, or replacing dysfunctional genes that cause disease to re-establish normal function as it is influencing the market growth. Financial-based agreements and health outcomes-based agreements have been proposed or implemented to improve therapy accessibility and market survival. These models have significantly impacted the adoption of therapies in the market. However, European biopharmaceutical firms have taken several steps to achieve a strategic advantage. Companies use various market penetration techniques, such as expanding biopharmaceutical facilities, collaborating with other primary partners, and collaborating with Contract Manufacturing Organizations (CMOs).

Progress in current R&D has been sluggish as several universities have shut down and suspended all non-essential testing and enrollment procedures for clinical trials. The high cost of gene therapy, on the other hand, is likely to restrict market growth to a certain extent during the projected period. Stringent government regulations by the government in European countries on the gene therapy market are considered the major growth decline factor for market growth.

Impact of COVID-19 on the European Gene Therapy Market:

The European cell and gene therapy market has been affected by COVID-19. The majority of the raw materials required for cell and gene therapy can't get to the factories due to the ban on transportation. Patients and volunteers for cell therapy cannot visit hospitals, limiting the market for cell and gene therapy in Europe. The gene therapy sector's research and clinical growth, and industrial activities have been disrupted. Gene therapy research has remained relatively unaffected at the end of the forecast period. However, the market is anticipated to witness significant growth in the coming years. 

This research report on the European Gene Therapy Market has been segmented & sub-segmented into the following categories:

 By Vector Type:

  • Viral vector
    • Retroviruses
    • Lentiviruses
    • Adenoviruses
    • Adeno-associated Virus
    • Herpes Simplex Virus
    • Poxvirus
    • Vaccinia Virus
    • Others
  • Non-viral vector
    • Naked/Plasmid Vectors
    • Gene Gun
    • Electroporation
    • Lipofection
    • Others

By Application:

  • Oncological Disorders
  • Rare Diseases
  • Cardiovascular Diseases
  • Neurological Disorders
  • Infectious disease
  • Other Diseases

By Country:

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of Europe

The Gene therapy market has witnessed significant growth in Europe over the years, and it is expected to have a promising growth rate during the forecast period. It increases healthcare expenditures, and introducing emerging technology in health care drives demand growth in this region. Hospitals are growing at a significant rate due to the increasing target population in Europe. In Europe, the United Kingdom gene therapy market had the largest share in 2020 and is expected to grow at a robust CAGR during the forecast period. In the health sciences and pharmaceutical sectors, gene therapy is seen as a future breakthrough. Despite the limited number of drugs that have made it to market, the number of clinical trials investigating gene therapy is rising in Europe. Delivering cell and gene therapies necessitates specialist equipment, capabilities, and clinician expertise. Cell and gene therapies can cure various severe disorders that aren't treatable by traditional approaches, fuelling the country's market growth.

The German gene therapy market is growing at a notable CAGR for a couple of years and is projected to share lucrative growth to the European market. Due to the expanded target population, provision of reimbursements, and novel payment solutions for cell and gene therapies in Germany, the Country accounted for the largest share of the European cell and gene therapy market, accounting for more than 20%.

KEY MARKET PLAYERS:

Some of the noteworthy companies operating in the European gene therapy market analyzed in this report are Biogen, Sarepta Therapeutics, Gilead Sciences, Inc., Amgen, Inc., Novartis AG, Orchard Therapeutics Plc, Spark Therapeutics, Inc., Molmed S.P.A., Anges, Inc., Bluebird Bio, Inc., Jazz Pharmaceuticals Plc, Dynavax Technologies, Human Stem Cells Institute, Sibiono Genetech Co., Ltd., Shanghai Sunway Biotech Co., Ltd., Uniqure N.V., Gensight Biologics S.A., Celgene Corporation, Cellectis, Sangamo Therapeutics, Mustang Bio, Applied Genetic Technologies Corporation and Poseida Therapeutics, Inc.

  1. INTRODUCTION
    1. Market Definition
    2. Study Deliverables
    3. Base Currency, Base Year and Forecast Periods
    4. General Study Assumptions
  2. RESEARCH METHODOLOGY
    1. Introduction
    2. Research Phases
      1. Secondary Research
      2. Primary Research
      3. Econometric Modelling
      4. Expert Validation
    3. Analysis Design
    4. Study Timeline
  3. Report Overview
    1. Executive Summary
    2. Key Inferences
  4. Market Dynamics
    1. Impact Analysis
      1. Drivers
      2. Restraints
      3. Opportunities       
    2. Regulatory Environment
    3. Technology Timeline & Recent Trends
  5. Competitor Benchmarking Analysis
    1. Key Player Benchmarking                    
      1. Market share analysis      
      2. Products/Service
      3. Regional Presence               
    2. Mergers & Acquisition Landscape                     
    3. Joint Ventures & Collaborations
  6. MARKET SEGMENTATION
    1. By Vector Type
      1. Viral vector
        1. Retroviruses
        2. Lentiviruses
        3. Adenoviruses
        4. Adeno-associated Virus
        5. Herpes Simplex Virus
        6. Poxvirus
        7. Vaccinia Virus
        8. Others
      2. Non-viral vector
        1. Naked/Plasmid Vectors
        2. Gene Gun
        3. Electroporation
        4. Lipofection
        5. Others
      3. Y-o-Y Growth Analysis, By Vector Type
      4. Market Attractiveness Analysis, By Vector Type
      5. Market Share Analysis, By Vector Type
    2. By Application
      1. Oncological Disorders
      2. Rare Diseases
      3. Cardiovascular Diseases
      4. Neurological Disorders
      5. Infectious disease
      6. Other Diseases
      7. Y-o-Y Growth Analysis, By Application
      8. Market Attractiveness Analysis, By Application
      9. Market Share Analysis, By Application
  7. GEOGRAPHICAL ANALYSIS
    1. Introduction
      1. Regional Trends
      2. Impact Analysis
      3. Y-o-Y Growth Analysis
      4. Market Attractiveness Analysis
      5. Market Share Analysis
    2. Europe
      1. Introduction
      2. U.K
      3. Spain
      4. Germany
      5. Italy
      6. France
      7. Rest of Europe
  8. STRATEGIC ANALYSIS
    1. PESTLE analysis
      1. Political
      2. Economic
      3. Social
      4. Technological
      5. Legal
      6. Environmental
    2. Porter’s Five analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Consumers
      3. Threat of New Entrants
      4. Threat of Substitute Products and Services
      5. Competitive Rivalry within the Industry
  9. MARKET LEADERS' ANALYSIS
    1. Biogen
      1. Overview
      2. Products
      3. Financials (subjected to availability based on company type)
      4. Recent Developments
      5. SWOT analysis
      6. Analyst View
    2. Sarepta Therapeutics
    3. Gilead Sciences, Inc.
    4. Amgen, Inc.
    5. Novartis AG
    6. Orchard Therapeutics Plc
    7. Spark Therapeutics, Inc.
    8. Molmed S.P.A.
    9. Anges, Inc.
    10. Bluebird Bio, Inc.
    11. Jazz Pharmaceuticals Plc
    12. Dynavax Technologies
    13. Human Stem Cells Institute
    14. Sibiono Genetech Co., Ltd.
    15. Shanghai Sunway Biotech Co., Ltd.
    16. Uniqure N.V.
    17. Gensight Biologics S.A.
    18. Celgene Corporation
    19. Cellectis
    20. Sangamo Therapeutics
    21. Mustang Bio
    22. Applied Genetic Technologies Corporation
    23. Poseida Therapeutics, Inc.
  10. COMPETITIVE LANDSCAPE
    1. Market share analysis
    2. Merger and Acquisition Analysis
    3. Agreements, collaborations and Joint Ventures
    4. New Product Launches
  11. MARKET OUTLOOK AND INVESTMENT OPPORTUNITIES
  12. APPENDIX
  13. List of Tables
  14. List of Figures
  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped.
  • Segment-level analysis in terms of vector type and application along with market size forecasts and estimations to detect key areas of industry growth in detail.
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics.
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis.
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development.
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment.
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies.
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions.
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market.
  1. Europe Gene Therapy Market, By Vector Type, From 2021 to 2026 (USD Million)
  2. Europe Viral vector Market, By Region, From 2021 to 2026 (USD Million)
  3. Europe Non-viral vector Market, By Region, From 2021 to 2026 (USD Million)
  4. Europe Gene Therapy Market, By Application, From 2021 to 2026 (USD Million)
  5. Europe Oncological Disorders Market, By Region, From 2021 to 2026 (USD Million)
  6. Europe Rare Diseases Market, By Region, From 2021 to 2026 (USD Million)
  7. Europe Cardiovascular Diseases Market, By Region, From 2021 to 2026 (USD Million)
  8. Europe Neurological Disorders Market, By Region, From 2021 to 2026 (USD Million)
  9. Europe Infectious disease Market, By Region, From 2021 to 2026 (USD Million)
  10. Europe Other Diseases Market, By Region, From 2021 to 2026 (USD Million)
  11. U.K. Gene Therapy Market, By Vector Type, From 2021 to 2026 (USD Million)
  12. U.K. Gene Therapy Market, By Application, From 2021 to 2026 (USD Million)
  13. Germany Gene Therapy Market, By Vector Type, From 2021 to 2026 (USD Million)
  14. Germany Gene Therapy Market, By Application, From 2021 to 2026 (USD Million)
  15. France Gene Therapy Market, By Vector Type, From 2021 to 2026 (USD Million)
  16. France Gene Therapy Market, By Application, From 2021 to 2026 (USD Million)
  17. Italy Gene Therapy Market, By Vector Type, From 2021 to 2026 (USD Million)
  18. Italy Gene Therapy Market, By Application, From 2021 to 2026 (USD Million)
  19. Spain Gene Therapy Market, By Vector Type, From 2021 to 2026 (USD Million)
  20. Spain Gene Therapy Market, By Application, From 2021 to 2026 (USD Million)
  21. Europe Gene Therapy Market, By Viral vector, From 2021 to 2026 (USD Million)
  22. Europe Retroviruses Market, By Region, From 2021 to 2026 (USD Million)
  23. Europe Lentiviruses Market, By Region, From 2021 to 2026 (USD Million)
  24. Europe Adenoviruses Market, By Region, From 2021 to 2026 (USD Million)
  25. Europe Adeno-associated Virus Market, By Region, From 2021 to 2026 (USD Million)
  26. Europe Herpes Simplex Virus Market, By Region, From 2021 to 2026 (USD Million)
  27. Europe Poxvirus Market, By Region, From 2021 to 2026 (USD Million)
  28. Europe Vaccinia Virus Market, By Region, From 2021 to 2026 (USD Million)
  29. U.K. Gene Therapy Market, By Viral vector, From 2021 to 2026 (USD Million)
  30. Germany Gene Therapy Market, By Viral vector, From 2021 to 2026 (USD Million)
  31. France Gene Therapy Market, By Viral vector, From 2021 to 2026 (USD Million)
  32. Italy Gene Therapy Market, By Viral vector, From 2021 to 2026 (USD Million)
  33. Spain Gene Therapy Market, By Viral vector, From 2021 to 2026 (USD Million)
  34. Europe Gene Therapy Market, By Non-viral vector, From 2021 to 2026 (USD Million)
  35. Europe Naked/Plasmid Vectors Market, By Region, From 2021 to 2026 (USD Million)
  36. Europe Gene Gun Market, By Region, From 2021 to 2026 (USD Million)
  37. Europe Electroporation Market, By Region, From 2021 to 2026 (USD Million)
  38. Europe Lipofection Market, By Region, From 2021 to 2026 (USD Million)
  39. Europe Others Market, By Region, From 2021 to 2026 (USD Million)
  40. U.K. Gene Therapy Market, By Non-viral vector, From 2021 to 2026 (USD Million)
  41. Germany Gene Therapy Market, By Non-viral vector, From 2021 to 2026 (USD Million)
  42. France Gene Therapy Market, By Non-viral vector, From 2021 to 2026 (USD Million)
  43. Italy Gene Therapy Market, By Non-viral vector, From 2021 to 2026 (USD Million)
  44. Spain Gene Therapy Market, By Non-viral vector, From 2021 to 2026 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample